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Some new proposals for the classification of inherited 
myopathies
Dear Editor,
In a recent publication in the Journal of the Neurological Sciences, we
highlighted the current difficulties in classifying the various forms of
inherited myopathies [1]. These suggestions were based on our initial
proposals for Charcot-Marie-Tooth disease (CMT) and other neuroge-
netic disorders) [2]. Recently, we conducted an internet survey to
evaluate the interest of the scientific community: 65% of the people
consulted considered that changes are needed and that our proposals
constitute an improvement over the historical classification of CMT [3,
4]. There have also been recent attempts to solve such problems in
other neurogenetic disorders such as hereditary ataxias [5]. We are
aware that any new classification of neuromuscular disorders will need
to be discussed in the neurological and genetic communities, but we
have proposed simplifying the classification of inherited muscular dis-
orders by using the same three successive steps: clinical phenotype,
mode of inheritance, then the name of the causative gene (Fig. 1A) [1].
We would like to make an alternative proposal for a ‘universal
method’ of classifying genetic disorders. In fact, it may be possible to
completely redesign the naming of hereditary muscular disorders,
based on the practical method of diagnosis in these diseases, which is
the aim of our second proposal based on the main features (clinical,
pathological, electrophysiological or radiological) employed in the di-
agnostic pathway of myopathy (whether dystrophic or not). Concerning
step 1 (ie the first element appearing in the list of a database), it can be
split into two successive modules (Fig. 1B). The first module of the ‘step
1’ corresponds to the ‘generic term’ of the entity, namely ‘HM’, for
‘hereditary myopathy’. We have selected this term because of the large
heterogeneity of muscular disorders: moreover, by using it, the term
HM appears first in a database. For inherited neuropathies, the phe-
notypes are limited to three: CMT, dHMN (distal hereditary motor
neuropathy) and HSAN (hereditary sensory and autonomic neuro-
pathies); the same is true for other neurogenic diseases (SPG, etc.).
Fig. 1. A: first proposal for the classification of inherited myopathies (published in Journal of the Neurological Science) [1]. B: alternative proposal for the classification
of the inherited myopathies (and other neurogenetic disorders, in grey box).
(AD: autosomal dominant; AR: autosomal recessive; Ax: axonal; BMD: Becker muscular dystrophy; CA: hereditary cerebellar ataxia; CAPM: Cap myopathy; Cardi-
omyo: cardiomyopathy; CCD: central core disease; CM: congenital myopathy; CMD: congenital muscular dystrophy; CNM: centronuclear myopathy; CUMDU1:
congenital neuromuscular disease with uniform type 1 fiber; De: demyelinating; dHMN: distal hereditary motor neuropathy; DMD: Duchenne muscular dystrophy;
EMARDD: early-onset myopathy, areflexia, respiratory distress and dysphagia; FSH: facioscapulohumeral dystrophy; FTD: fiber-type dysproportion HM: hereditary
myopathy; HSAN: hereditary sensory and autonomic neuropathy; IBM: inclusion body myopathy; In: intermediate; LGMD: limb-girdle muscular dystrophy; MD:
muscular dystrophy; MEB: muscle eye brain syndrome; Mit: mitochondrial inheritance; MMD: multiminicore disease; MSM: myosin storage myopathy; MTM:
myotubular myopathy; MYPCN: Compton-North congenital myopathy; NEM: nemaline myopathy; NS: non-specific; OPG: oculopharyngeal; Ophthalm (or OP):
ophthalmoplegia; PP: periodic paralysis; SPG: hereditary spastic paraplegia; VCPDN: vocal cord and pharyngeal dysfunction with distal myopathy; Spo: sporadic;
WWS: Walker-Warburg syndrome; XL: X-linked).
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The two next parts of the ‘step 1’ include the ‘clinical phenotype’ (II:
proximal, distal, joint contracture, etc.) and/or the ‘pathological phe-
notype’ (III: dystrophic, myofibrillar, etc.), into brackets (clinical and
pathological parts being separated by a slash when both are used);
moreover, it may also be possible to invert II and III. However, it is
likely that molecular biological methods might soon supplant muscular
biopsy in the determination of the pathological phenotype. Based on
our experience, we propose a non-exhaustive list for each part (Fig. 1B):
the type of myopathy affecting the patient is thus readily identified. It is
also possible to group some clinical entities, such as MEB (Muscle-Eye-
Brain) or WWS (Walker-Warburg syndrome), in the same group that we
may name ‘plus’. In addition, other (not yet described) forms of HM can
be added and it removes certain ambiguous terms such as ‘LGMD’
(because some myopathies with proximal involvement are not classified
as LGMD when they might be) or ‘congenital myopathy’ (for which
some authors also include late-onset forms of hereditary myopathy). In
order to retain the term ‘LGMD’, we propose using ‘LG’ (=limb girdle),
even if we think that the term ‘proximal’ is better: thus, muscular
dystrophy with predominant proximal involvement (whether LGMD or
not) would become ‘HM(LG/dystrophic)-…’; for example, LGMD2L
would become ‘HM(LG/dystrophic)-AR-ANOS5’. In such a classifica-
tion, most eponyms (which often complicate classifications) are dis-
carded. Another advantage is also the ease of distinguishing dystrophic
processes from non-dystrophic processes. For CMT, the ‘clinical phe-
notype’ (or ‘electro-clinical phenotype’) is limited to ‘De’ (demyeli-
nating), ‘Ax' (axonal) and ‘In’ (intermediate) which is a simplification;
for the other neurogenetic diseases (such as spastic paraplegia), it is not
necessary to put any term in brackets. For ‘step 2′ (mode of transmis-
sion), we retain the classical ‘AD’ (autosomal-dominant), ‘AR’ (auto-
somal-recessive), ‘X' (X-linked), ‘mit’ (mitochondrial transmission), and
‘unknown’ (if unknown inheritance). We do not feel that is necessary to
specify whether it is a congenital form or not; however, ‘C' (in brackets)
could be added directly after the inheritance (for example: …-AD(C)-
…) if needed. Finally, ‘step 3′ remains the same, including the name of
the gene or ‘unknown’ (if gene is unknown).
We are not alone in thinking that the current classifications of HM
are too heterogeneous and complex, even for specialists. It is why we
have now presented two proposals of classification which also simplify
the terminology. These proposals will need to be discussed by other
experts in myology, neuropathology and genetics. We also note that it
may be possible and convenient to use the same structure of classifi-
cation for any neuro-degenerative disorder [2].
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